ZANTAC IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZANTAC IN PLASTIC CONTAINER (ZANTAC IN PLASTIC CONTAINER).
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
| Metabolism | Primarily hepatic metabolism via N-oxidation, N-dealkylation, and S-oxidation; minimal first-pass metabolism; cytochrome P450 involvement not significant. |
| Excretion | Renal: 70% (unchanged drug); Hepatic metabolism: 30% (minor N-oxide, S-oxide, and desmethyl metabolites); Biliary/fecal: negligible. |
| Half-life | Terminal elimination half-life: 2.5–3 hours; prolonged to 4–5 hours in elderly or moderate renal impairment; accumulates in severe renal failure (CrCl <10 mL/min). |
| Protein binding | 15% bound, primarily to albumin. |
| Volume of Distribution | Approximately 1.2–1.4 L/kg; distributes widely into tissues, including breast milk and placenta. |
| Bioavailability | Oral: 50% (first-pass metabolism); IM: 90–100%. |
| Onset of Action | Oral: 30 minutes; IV: within minutes; IM: 10–15 minutes. |
| Duration of Action | Oral: 4–8 hours (single dose), 10–12 hours with repeated dosing; IV: 4–6 hours; IM: 6–8 hours. |
| Molecular Weight | 350.87 |
150 mg orally twice daily or 50 mg intravenously every 6 to 8 hours.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl <50 mL/min: reduce dose to 150 mg orally once daily or 50 mg intravenously every 12 to 24 hours. |
| Liver impairment | No specific adjustment recommended for hepatic impairment; use with caution. |
| Pediatric use | 1 month to 16 years: 2 to 4 mg/kg orally twice daily; maximum 150 mg twice daily. IV: 2 to 4 mg/kg/day divided every 6 to 8 hours. |
| Geriatric use | Consider reduced starting dose due to increased risk of confusion and adverse effects; adjust based on renal function. |
| 1st trimester | Ranitidine crosses the placenta. Human data do not suggest an increased risk of major congenital malformations. Use only if clearly needed. |
| 2nd trimester | No evidence of fetal harm in animal studies; limited human data. Use if benefit outweighs risk. |
| 3rd trimester | No reported adverse fetal effects; consider use for GERD during pregnancy if indicated. |
Clinical note
Comprehensive clinical and safety monograph for ZANTAC IN PLASTIC CONTAINER (ZANTAC IN PLASTIC CONTAINER).
| Placental transfer | Ranitidine crosses the placenta; cord blood levels are approximately 50% of maternal serum levels. Transfer occurs via passive diffusion. |
| Breastfeeding | Ranitidine is excreted into human milk in low concentrations. Peak milk levels occur 2-6 hours after maternal dose. The amount ingested by the infant is less than 7% of the maternal dose and is unlikely to cause adverse effects. May suppress gastric acid secretion in the nursing infant, but clinical significance is low. Use with caution. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to ranitidine or any component of the formulationAcute porphyria (may precipitate attacks)
| Precautions | May cause confusion, delirium, hallucinations, especially in elderly or severely ill patients, Use caution in patients with hepatic or renal impairment (reduce dose), May increase risk of pneumonia in hospitalized patients, May cause vitamin B12 deficiency with prolonged use, Rapid IV administration may cause bradycardia, Use caution in acute porphyria |
| Food/Dietary | No significant food interactions. However, high-fat meals may delay absorption but do not require dose adjustment. Avoid excessive caffeine and alcohol as they may increase gastric irritation. For optimal effect, take ranitidine at bedtime if prescribed for nighttime symptoms. |
Loading safety data…
| Lactation Rating | L2 (Safely compatible) |
| Teratogenic Risk | Pregnancy category B. Animal studies show no fetal harm. No adequate human studies in first trimester. Second and third trimester: no evidence of risk from postmarketing surveillance. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal adverse effects (headache, dizziness, GI symptoms). |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. |
| Clinical Pearls | Zantac (ranitidine) is a histamine H2-receptor antagonist used to decrease gastric acid secretion. It is available in plastic containers for intravenous administration, typically in hospital settings. For IV infusion, ensure patency of IV line and monitor for injection site reactions. Tachyphylaxis can occur with prolonged use. Dose adjustment is required in renal impairment (CrCl < 50 mL/min). Ranitidine may interfere with creatinine tubular secretion, causing falsely elevated serum creatinine. It is contraindicated in patients with acute porphyria. Not recommended for use in patients with history of hypersensitivity to H2 antagonists. |
| Patient Advice | Take ranitidine exactly as prescribed; do not double doses if a dose is missed. · Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing. · Inform your doctor if you have kidney disease, liver disease, or porphyria. · Avoid smoking and alcohol as they may worsen stomach conditions and reduce drug effectiveness. · If taking antacids, separate administration by at least 1 hour. · For IV use: Report pain, redness, or swelling at the injection site. |